keyword
MENU ▼
Read by QxMD icon Read
search

Dupilumab

keyword
https://www.readbyqxmd.com/read/28708993/il-4r%C3%AE-inhibitor-for-atopic-disease
#1
Howard Y Chang, Kari C Nadeau
Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF.
July 13, 2017: Cell
https://www.readbyqxmd.com/read/28674469/pharmaceutical-approval-update
#2
Mary Choy
Niraparib (Zejula) for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; ocrelizumab (Ocrevus) for relapsing or primary progressive multiple sclerosis; and dupilumab (Dupixent) for moderate-to-severe atopic dermatitis.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28668106/atopic-dermatitis-treatment-current-state-of-the-art-and-emerging-therapies
#3
Jonathan I Silverberg
BACKGROUND: Atopic dermatitis (AD) can be debilitating and often requires the use of combination topical and systemic therapy to achieve adequate disease control. METHODS: A non-systematic review was performed of current state of the art and emerging therapies for AD. RESULTS: There are a number of topical agents approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD and multiple nonapproved systemic agents that are used off label for the treatment of AD...
July 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28658541/the-interplay-between-genetic-and-environmental-factors-in-the-pathogenesis-of-atopic-dermatitis
#4
REVIEW
Atsushi Otsuka, Takashi Nomura, Pawinee Rerknimitr, Judith A Seidel, Tetsuya Honda, Kenji Kabashima
Atopic dermatitis (AD) is a chronic skin disorder characterized by pruritus and recurrent eczematous lesions that are accompanied by T-helper (Th)2-dominated inflammation. AD Etiology is not yet completely understood, but it is multifactorial. Moreover, the disease is characterized by complex interactions between genetic and environmental factors, such as skin barrier dysfunctions, allergy/immunity, and pruritus. For example, filaggrin is a key protein involved in skin barrier function. Th2 cells produce interleukin (IL)-31, which provokes pruritus, and other Th2 cytokines decrease filaggrin expression by keratinocytes...
July 2017: Immunological Reviews
https://www.readbyqxmd.com/read/28654711/addressing-the-immunopathogenesis-of-atopic-dermatitis-advances-in-topical-and-systemic-treatment
#5
Lawrence F Eichenfield, Linda F Stein Gold
Several immunologic mediators-phosphodiesterase (PDE), interleukin (IL), small molecules, and Janus kinase-have been implicated in the pathogenesis of atopic dermatitis, and evidence has shown that blocking these mediators can help modify the disease process. Several new topical medications have been developed that target the enzyme PDE; crisaborole was recently approved by the US Food and Drug Administration (FDA) for the treatment of atopic dermatitis, and phase II studies have been completed on OPA-15406...
March 2017: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28652155/advances-in-atopic-dermatitis-and-urticaria-2016
#6
Tetsuya Honda, Takashi Nomura, Kenji Kabashima
This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis using human samples revealed different immune profiles between childhood AD and adult AD. Phase III clinical trials of dupilumab, an anti-IL4 receptor alpha antibody, on AD have successfully finished, and dupilumab will appear in clinical practice as the first biologics for AD in 2017. In addition, a novel biologics that targets IL-31 shows promising results in a phase II trial...
June 23, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28583618/new-anti-eosinophil-drugs-for-asthma-and-copd-targeting-the-trait
#7
REVIEW
Elisabeth H Bel, Anneke Ten Brinke
Asthma and chronic obstructive airways disease (COPD) are prevalent chronic inflammatory airway diseases that are responsible for a large global disease burden. Both diseases are complex and heterogeneous, and are increasingly recognized as overlapping syndromes that may share similar pathophysiologic mechanisms and treatable traits. Eosinophilic airway inflammation is considered the most influential treatable trait of chronic airway disease, and over the last decade several monoclonal antibodies and small molecule therapies have been developed to target this trait...
June 2, 2017: Chest
https://www.readbyqxmd.com/read/28555328/evolving-concepts-in-atopic-dermatitis
#8
REVIEW
Robert Sidbury, Kate Khorsand
PURPOSE OF REVIEW: Tremendous advances have been made in the field of atopic dermatitis in the past 5 years. We will explore developments in burden of disease, co-morbidities, pathogenesis, prevention, and management. RECENT FINDINGS: The tremendous burden moderate to severe atopic dermatitis (AD) places on families from a medical, psychosocial, and financial perspective has been characterized. Epidemiologic studies have identified intriguing new associations beyond the well-characterized "atopic march" of food allergies, asthma, and hay fever...
July 2017: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/28553077/spotlight-on-dupilumab-in-the-treatment-of-atopic-dermatitis-design-development-and-potential-place-in-therapy
#9
REVIEW
Angelo Massimiliano D'Erme, Marco Romanelli, Andrea Chiricozzi
Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28547386/dupilumab-first-global-approval
#10
REVIEW
Matt Shirley
Dupilumab (Dupixent(®)) is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α (IL-4Rα) subunit. Dupilumab inhibits the signalling of the type 2 cytokines IL-4 and IL-13 and was co-developed by Regeneron Pharmaceuticals and Sanofi as a potential therapeutic agent for the treatment of atopic or allergic diseases. In March 2017 dupilumab received its first global approval, in the USA, for use in the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable...
July 2017: Drugs
https://www.readbyqxmd.com/read/28503712/dupilumab-improves-general-health-related-quality-of-life-in-patients-with-moderate-to-severe-atopic-dermatitis-pooled-results-from-two-randomized-controlled-phase-3-clinical-trials
#11
Eric L Simpson
INTRODUCTION: Patients with moderate-to-severe atopic dermatitis (AD) report a multidimensional disease burden that includes impaired health-related quality-of-life (HRQoL). Changes in overall health status and specific dimensions that contribute to HRQoL were evaluated in adults with moderate-to-severe AD who participated in phase 3 clinical trials of dupilumab, which is a fully human monoclonal antibody that inhibits signaling of cytokines IL-4 and IL-13. METHODS: Two dupilumab phase 3 clinical trials of identical design included the 5-dimension 3-level EuroQol (EQ-5D) as a measure of HRQoL...
June 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/28479326/efficacy-and-safety-of-dupilumab-for-the-treatment-of-adult-atopic-dermatitis-a-meta-analysis-of-randomized-clinical-trials
#12
Yue Han, Yuxin Chen, Xiaochun Liu, Jingxi Zhang, Huichun Su, He Wen, Wei Li, Xu Yao
No abstract text is available yet for this article.
May 4, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28478973/dupilumab-for-atopic-dermatitis
#13
Lindsay C Strowd, Steven R Feldman
No abstract text is available yet for this article.
June 10, 2017: Lancet
https://www.readbyqxmd.com/read/28478972/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and-concomitant-topical-corticosteroids-liberty-ad-chronos-a-1-year-randomised-double-blinded-placebo-controlled-phase-3-trial
#14
Andrew Blauvelt, Marjolein de Bruin-Weller, Melinda Gooderham, Jennifer C Cather, Jamie Weisman, David Pariser, Eric L Simpson, Kim A Papp, H Chih-Ho Hong, Diana Rubel, Peter Foley, Errol Prens, Christopher E M Griffiths, Takafumi Etoh, Pedro Herranz Pinto, Ramon M Pujol, Jacek C Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M H Graham, Gianluca Pirozzi, Neil Stahl, George D Yancopoulos, Brad Shumel
BACKGROUND: Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis...
June 10, 2017: Lancet
https://www.readbyqxmd.com/read/28450716/fda-approves-dupilumab-for-severe-eczema
#15
Asher Mullard
No abstract text is available yet for this article.
April 28, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/28419072/dupilumab-dupixent-for-moderate-to-severe-atopic-dermatitis
#16
(no author information available yet)
No abstract text is available yet for this article.
April 24, 2017: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/28375933/use-of-biologics-in-severe-food-allergies
#17
Alessandro Fiocchi, Valentina Pecora, Rocco L Valluzzi, Vincenzo Fierro, Maurizio Mennini
PURPOSE OF REVIEW: Severe cases of food allergy account for the majority of the burden in terms of risks, quality of life, and resource expenditure. The traditional approach to these forms has been strict avoidance. More recently, Oral ImmunoTherapy (OIT) has gained a role in their management. However, in severe food allergies OIT is often infeasible. RECENT FINDINGS: Case reports, observational, and prospective studies have recently proposed different approaches to severe food allergy...
June 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28366479/biologic-therapy-in-the-treatment-of-chronic-skin-disorders
#18
REVIEW
James M Fernandez, Anthony P Fernandez, David M Lang
Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28281440/monoclonal-antibody-therapy-in-sinonasal-disease
#19
Sergio E Chiarella, Hendrik Sy, Anju T Peters
Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. POPULATION: CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP...
March 1, 2017: American Journal of Rhinology & Allergy
https://www.readbyqxmd.com/read/28277826/commonality-of-the-il-4-il-13-pathway-in-atopic-diseases
#20
Namita A Gandhi, Gianluca Pirozzi, Neil M H Graham
Allergy results from an aberrant Type 2 inflammatory response, triggered by a wide range of environmental antigens (allergens) that lead to various immune responses, culminating in the production of immunoglobulin E (IgE). Two key cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and perpetuation of the Type 2 response, and have been implicated in multiple atopic diseases. Area covered: This review summarizes recent milestone developments that have elucidated components of the pathogenesis of atopic diseases such as atopic dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP)...
March 15, 2017: Expert Review of Clinical Immunology
keyword
keyword
25750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"